Clinical trial
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
NCT00058487 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00058487 |
|---|---|
| Title | Epirubicin and Thalidomide in Treating Patients With Liver Cancer |
| Official title | A Phase II Study Of Epirubicin And Thalidomide In Unresectable Or Metastatic Hepatocellular Carcinoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | epirubicin hydrochloride, thalidomide |
| Enrollment | 12 |
| Start date | Dec 1, 2001 |
| Completion | Jan 1, 2007 |
| First posted | Apr 9, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: